Gene Therapy: A Candid Conversation

The realization that gene therapy could be just around the corner is both daunting and exciting. Join us for a balanced, patient-centric discussion on gene therapy from multiple perspectives: a provider, a patient in a gene therapy clinical trial, a patient on a newer therapy, and a patient who is satisfied with conventional factor replacement therapy.

Gene Therapy: Getting Up to Speed

Advancements in gene therapy are happening at a fast clip. Having a solid understanding of this technology is important to patients, caregivers and families. Join us for an in-depth discussion of gene therapy including historical aspects, key terms, various approaches to the technology, and how it may revolutionize hemophilia treatment.

From Principles to Practice: Preparing for the Advent of Gene Therapy

This activity is intended for hematologists, pediatricians, primary care physicians, nurses, and nurse practitioners. It is part of Medscape’s series “Clinical Advances in Gene Therapy for Hemophilia.” Presented through a collaboration between Medscape and the National Hemophilia Foundation, the series includes various discussions relevant to the latest data on gene therapy as well as the practicalities associated with using gene therapy for hemophilia.

Forging a New Path – Gene Therapy Readiness and HTC Implementation

*CME/ACPE

Moderator/Speaker:

Steven W. Pipe, MD, Faculty Chair
Professor of Pediatrics and Pathology
Laurence A. Boxer Research Professor of Pediatrics and Communicable Diseases,
Pediatric Medical Director, Hemophilia and Coagulation Disorders Program,
Director, Special Coagulation Laboratory,
University of Michigan
Ann Arbor, Michigan

Speakers:

Moving Beyond Factor: Shifting the Paradigm in Hemophilia Through Gene Therapy

This activity features an international panel of experts that review the science underlying therapy strategies, provide updates on the latest data for therapies in development, and critically evaluate the potential role gene therapy may play in patient care, both now and in the future. It is intended for hematologists, pediatric hematologists, and all members of the clinical care team involved in the care of patients with hemophilia.